Stay updated on SNS-101 and Cemiplimab Combo in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the SNS-101 and Cemiplimab Combo in Solid Tumors Clinical Trial page.

Latest updates to the SNS-101 and Cemiplimab Combo in Solid Tumors Clinical Trial page
- Check2 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe page now shows Revision: v3.5.4, indicating a minor update to the page's revision history.SummaryDifference0.0%

- Check24 days agoNo Change Detected
- Check39 days agoChange DetectedThe page’s footer/version label has been updated from “Revision: v3.5.2” to “Revision: v3.5.3,” reflecting a backend or display version change rather than a change to the clinical study details.SummaryDifference0.0%

- Check46 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check67 days agoChange DetectedAdded the MeSH term 'Cutaneous neuroendocrine carcinoma' and updated the page revision from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check89 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3 on the page.SummaryDifference0.0%

- Check110 days agoChange DetectedGastric cancer was added to the list of conditions for the study, broadening the potential population the page pertains to. A new Genetic and Rare Diseases Information Center resource was added under Resources, and the site revision banner updated from v3.4.1 to v3.4.2.SummaryDifference0.2%

Stay in the know with updates to SNS-101 and Cemiplimab Combo in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SNS-101 and Cemiplimab Combo in Solid Tumors Clinical Trial page.